Copyright
©The Author(s) 2023.
World J Gastroenterol. Sep 7, 2023; 29(33): 4942-4961
Published online Sep 7, 2023. doi: 10.3748/wjg.v29.i33.4942
Published online Sep 7, 2023. doi: 10.3748/wjg.v29.i33.4942
Table 4 Drug classes and corresponding risk of hepatitis B virus reactivation[6]
Drug class | Drug or dose | Risk of HBV reactivation | |
For HBsAg-positive patients | For HBsAg-negative/anti-HBc-positive patients | ||
Anti-CD20 monoclonal antibodies | Rituximab, obinutuzumab, ofatumumab | High (30%-60%) | High (> 10%) |
Anthracycline chemotherapy | Doxorubicin, daunorubicin, epirubicin | High (15%-30%) | High (> 10%) |
Steroids | Moderate/high dose ≥ 4 wk | High (> 10%) | Moderate (1%-10%) |
Low dose ≥ 4 wk | Moderate (1%-10%) | Low (< 1%) | |
Low dose ≤ 1 wk | Low (< 1%) | Low (< 1%) | |
Tyrosine kinase inhibitors | Imatinib, nilotinib, dasatinib | High to moderate | Low (< 1%) |
Immune checkpoint inhibitors | Nivolumab, pembrolizumab | High (> 10%) | Uncertain |
Proteasome inhibitor | Bortezomib | Moderate (1%-10%) | Moderate (1%-10%) |
- Citation: Mak JWY, Law AWH, Law KWT, Ho R, Cheung CKM, Law MF. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era. World J Gastroenterol 2023; 29(33): 4942-4961
- URL: https://www.wjgnet.com/1007-9327/full/v29/i33/4942.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i33.4942